Post Marketing Surveillance Study for MenQuadfi® [Meningococcal (Groups A, C, Y, W) Polysaccharide Tetanus Toxoid Conjugate Vaccine] Administered in Participants Aged 6 Weeks to 55 Years in Republic of Korea

This surveillance is to investigate the safety profile of MenQuadfi®, when administered to participants aged 6 weeks to 55 years under the real-world clinical practice settings as per approved indications, including the Adverse Drug Reactions (ADRs)\*. \*It includes ADRs that were not fully recognized in clinical practice, or unexpected ADRs which refer to those not listed in the approved drug labeling.

NCT Number	NCT07621653
Lead Sponsor	Sanofi
Conditions	Meningococcal Immunization, Healthy Volunteers
Enrollment	706 participants
Start Date	2026-07-01
Primary Completion	2027-11-23 (estimated)
Study Completion	2027-11-23 (estimated)
Updated on ClinicalTrials.gov	2026-07-29